 Patients This multicentre prospective cohort study will be conducted at three sites in Nottingham Nottingham University Hospitals, London Northwick Park NHS Foundation Trust and Manchester Salford Royal NHS Foundation Trust. A total of 20 patients age 16-75 years with pCD as deemed by a PDAI of 4 and a clinician assessment, prior to the onset of biological therapy. All eligible patients will receive infliximab or adalimumab or Ustekinumab. Patients will have infliximab 5 mgkg i.v. at weeks 0, 2, 6 and 8 weekly thereafter, or Adalimumab subcutaneously s.c. at week 0 160 mg, 2 80mg, 40 mg every 2 weeks thereafter or Ustekinumab 6mgkg i.v. at week 0 and a weight-based s.c. every 12 weeks thereafter. Patients will be excluded from the study if they are due to have surgery in the near future 12 weeks. 